Uplizna (inebilizumab) Medical Benefit Medication Utilization Policy
Customize your policy alerts
Sign up for all Community-Care policy alerts
Know when Community-Care releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity criteria, quantity limits, authorization periods, and coding for inebilizumab (Uplizna) when administered as a medical benefit for specific indications; applies to providers seeking prior authorization from the payer for patients in North Carolina.
No material clinical or coverage changes in this revision.
Coverage criteria for inebilizumab (Uplizna)
Initial Therapy — Covered when ALL of the following are met for each indication
Covered when ALL of the following are met for each indication
Continuation Therapy — Continued coverage requires ALL of the following per indication
Continued coverage requires ALL of the following per indication
Quantity Limits — Coverage is subject to the following quantity limits
Coverage is subject to the following quantity limits
Use of inebilizumab (Uplizna) in combination with another biologic product indicated for neuromyelitis optica spectrum disorder is not permitted. Requests for initial or continued therapy must document that the drug will be used as monotherapy for NMOSD and will not be administered together with any other NMOSD-targeted biologic agent.
Billing and coding
| J1823 | Injection, inebilizumab-cdon, 1 mg |
Requirements and actions for providers
Prior authorization required with supporting documentation
Prior authorization is required for inebilizumab (J1823) and must be submitted with documentation that supports the requested diagnosis, involvement of an appropriate specialist, and relevant laboratory or treatment history per the indication-specific criteria.
- Applicable code: J1823
No further step therapy beyond corticosteroid requirement for IgG4-related disease
There is no additional step therapy sequence specified in this policy beyond the requirement for a trial of corticosteroids (or documentation of corticosteroid intolerance/contraindication) for IgG4-related disease.
- For IgG4-related disease, a trial of a corticosteroid that was ineffective, contraindicated, or not tolerated must be documented.
Required documentation to support authorization
Documentation submitted with the authorization request must include the patient’s diagnosis and evidence of specialist involvement, and for NMOSD must include a positive anti‑aquaporin‑4 antibody test; for IgG4‑related disease include documentation of a corticosteroid trial that was ineffective, contraindicated, or not tolerated.
- NMOSD: positive anti‑AQP4 antibody test; prescribed by or in consultation with a neurologist or neuro‑ophthalmologist
- IgG4-related disease: prescribed by or in consultation with a rheumatologist or specialist; documentation of corticosteroid trial failure, contraindication, or intolerance
Triggers for denial
Requests may be denied if they do not include the required diagnosis, lack prescriber specialty or documented consultation, do not provide a positive AQP4 antibody test when seeking treatment for NMOSD, or fail to document a corticosteroid trial failure/contraindication/intolerance for IgG4‑related disease.
- Missing diagnosis of NMOSD or IgG4‑related disease
- No documentation that prescription was by, or in consultation with, the appropriate specialist
- No positive anti‑aquaporin‑4 antibody test when indicated for NMOSD
- For IgG4-related disease, no documentation of corticosteroid trial failure, contraindication, or intolerance
Background
Inebilizumab (Uplizna) is a monoclonal B‑cell depleting biologic indicated for treatment of neuromyelitis optica spectrum disorder associated with anti‑aquaporin‑4 antibodies. Use for NMOSD should be coordinated with a neurologist or neuro‑ophthalmologist and requires documentation of a positive anti‑AQP4 antibody test. The agent is also considered for immunoglobulin G4‑related disease when prescribed by or in consultation with an appropriate specialist and after a trial of corticosteroids has been ineffective, contraindicated, or not tolerated.
Key definitions
Initial therapy criteria (detailed by indication)
Initial Therapy — Initial therapy criteria per indication
Initial therapy criteria per indication
Continuation therapy criteria (detailed by indication)
Continuation Therapy — Continuation coverage requirements per indication
Continuation coverage requirements per indication
Step therapy requirements
| Step | Requirement |
|---|---|
| 1 | No other step therapy requirements specified beyond the requirement that, for IgG4‑related disease, a trial of corticosteroids was ineffective, contraindicated, or not tolerated. |
| 2 | For IgG4‑related disease, documentation of corticosteroid trial failure, intolerance, or contraindication is required prior to approval; no additional medication step sequence is specified. |
Quantity limits and dosing caps
Site of care considerations
No site‑of‑care restriction specified
The policy does not impose site‑of‑care restrictions; infusion may be administered in an infusion center per usual practice.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.